Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS: Durvalumab in Borderline Resectable Stage III NSCLC
NCT06998719Phase 2Not yet recruiting
- Sponsor
- BiNan
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by BiNan. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06998719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998719.